Exploration of the in-vitro pharmacodynamic activity of moxifloxacin for Staphylococcus aureus and streptococci of Lancefield groups A and G

Journal of Antimicrobial Chemotherapy

Volumn 44, Issue 6, 1999, Pages 761-766

  MacGowan, Alasdair P ^a   Bowker, Karen E ^a   Wootton, Mandy ^a   Holt, H Alan ^a  

^a SOUTHMEAD HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; MOXIFLOXACIN;

AREA UNDER THE CURVE; ARTICLE; BACTERIAL COUNT; BACTERICIDAL ACTIVITY; BACTERIUM CULTURE; DRUG BLOOD LEVEL; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; SIMULATION; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS GROUP A; STREPTOCOCCUS GROUP G;

EID: 0032763696     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/44.6.761     Document Type: Article

References (16)

1. Dalhoff, A., Petersen, U. & Endermann, R. (1996). In vitro activity of BAY 12-8039, a new 8-methoxyquinolone. Chemotherapy 42, 410-25.
2. Woodcock, J. M., Andrews, J. M., Boswell, F. J., Brenwald, N. P. & Wise, R. (1997). In vitro activity of BAY 12-8039, a new fluoroquinolone. Antimicrobial Agents and Chemotherapy 41, 101-6.
3. Bauernfeind, A. (1997). Comparison of the antibacterial activities of the quinolones Bay 12-8039, gatifloxacin (AM 1155), trovafloxacin, clinafloxacin, levofloxacin and ciprofloxacin. Journal of Antimicrobial Chemotherapy 40, 639-51.
4. Boswell, F. J., Andrews, J. M. & Wise, R. (1997). Pharmaco-dynamic properties of BAY 12-8039 on Gram-positive and Gram-negative organisms as demonstrated by studies of time-kill kinetics and post antibiotic effect. Antimicrobial Agents and Chemotherapy 41, 1377-9.
5. Bowker, K. E., Wootton, M., Holt, H. A., Reeves, D. S. & MacGowan, A. P. (1997). Bactericidal activity of Bay 12-8039, against Streptococcus pneumoniae explored using an in-vitro continuous bacterial culture model. In Abstracts of the Thirty-Seventh Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada, 1997. Abstract F-134, p. 169. American Society for Microbiology, Washington, DC.
6. Lister, P. D. & Sanders, C. C. (1998). Pharmacodynamics of moxifloxacin against Streptococcus pneumoniae in an in-vitro pharmacokinetic model. In Abstracts of the Thirty-Eighth Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, 1998. Abstract A-21, p. 7. American Society for Microbiology, Washington, DC.
7. Zinner, S., Gilbert, D., Simmons, K. & Sarlak, E. (1998). Moxifloxacin activity against S. pneumoniae in an in-vitro dynamic model. In Abstracts of the Thirty-Eighth Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, 1998. Abstract A-26, p. 8. American Society for Microbiology, Washington, DC.
8. Bowker, K. E., Wootton, M., Holt, H. A. & MacGowan, A. P. (1998). In-vitro activity of moxifloxacin against Haemophilus influenzae and Moraxella catarrhalis investigated using a pharmaco-dynamic model of infection. In Abstracts of the Thirty-Eighth Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, 1998. Abstract E-207, p. 229. American Society for Microbiology, Washington, DC.
9. British Society for Antimicrobial Chemotherapy. (1991). A Guide to Sensitivity Testing: Report of the Working Party on Antibiotic Sensitivity Testing of the British Society for Antimicrobial Chemotherapy. Academic Press, London.
10. Stass, H., Dalhoff, A., Kubitza, D. & Schuhly, U. (1998). Pharmacokinetics, safety and tolerability of ascending single doses of moxifloxacin, a new 8-methoxyquinolone, administered to healthy subjects. Antimicrobial Agents and Chemotherapy 42, 2060-5.
11. Broughall, J. M. (1978). Aminoglycosides. In Laboratory Methods in Antimicrobial Chemotherapy, (Reeves, D. S., Phillips, I., Williams, J. D. & Wise, R., Eds), pp. 194-206. Churchill Livingstone, Edinburgh.
12. Corvaisier, S., Maive, P. H., Bouvier d'Yvoire, M. Y., Barbaut, X., Bleyzac, N. & Jelliffe, R. W. (1998). Comparisons between antimicrobial pharmacodynamic indices and bacterial killing as described by using the Zhi model. Antimicrobial Agents and Chemotherapy 42, 1731-7.
13. Dalhoff, A. (1996). Antibacterial efficacy of fluctuating concentrations of Bay 12-8039 simulating human serum kinetics. In Abstracts of the Thirty-Sixth Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, LA, 1996. Abstract F-26, p. 104. American Society for Microbiology, Washington, DC.
14. Vesga, O., Conklin, R., Stamstad, T. & Craig, W. A. (1996). Pharmacodynamic activity of Bay 12-8039 in animal infection model. In Abstracts of the Thirty-Sixth Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, LA, 1996. Abstract F-22, p. 103. American Society for Microbiology, Washington, DC.
15. Ostergaard, C., Sorensen, T. K., Knudsen, J. D. & Frimodt-Moller, N. (1998). Evaluation of moxifloxacin, a new 8 methoxyquinolone, for treatment of meningitis caused by a penicillin-resistant pneumococcus in rabbits. Antimicrobial Agents and Chemotherapy 42, 1706-12.
16. Preston, S. L., Drusano, G. L., Berman, A. L., Fowler, C. L., Chow, A. T., Dornseif, B. et al. (1998). Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials. Journal of the American Medical Association 279, 125-9.